DOCSLIB.ORG

Anti-Idiotype Antibody Generation and Application in Antibody Drug Discovery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Idiotype Antibody Generation and Application in Antibody Drug Discovery Anti-idiotype Antibody Generation and Application in Antibody Drug Discovery Liusong Yin, PhD Senior Scientist, Group Leader Antibody Discovery, Antibody Department, GenScript [email protected] Apr 21st, 2016 Presentation Overview Anti-idiotype antibody introduction 1 2 Anti-idiotype antibody application 3 Anti-idiotype antibody development 4 Anti-idiotype antibody case study Make Research Easy 2 Structural overview of antibodies PDB ID: 1HZH Liusong Yin, 2014, A Dissertation Make Research Easy 3 Antibody ‘-types’ Isotype (species specific)– the phenotypic variations in the constant regions of the heavy and light chains Allotype (animal specific)– the genetically determined difference in antibodies between individuals in the same species, mainly a couple AA differences in constant region Idiotype (antigen specific)– the antigen binding specificity defined by the distinctive sequence in the variable region of antibodies Make Research Easy 4 ‘-topes’ in anti-idiotype antibodies (anti-IDs) Idiotope – the antigenic determinants in or close to the complementarity determining region (CDR) in variable region Epitope Paratope Paratope – the part of an Ab that recognizes an antigen, the antigen-binding site of an Ab Epitope – the part of the antigen to which the paratope binds Anti-IDs – anti-idiotype antibodies which recognize the shared feature of idiotopes Make Research Easy 5 Different types of Anti-IDs Antigen-blocking Non-blocking Complex-specific Anti-ID Drug Target Anti-ID Anti-ID Antibody drug Antibody drug Antibody drug • Paratope-specific • Not paratope-specific • Drug-target complex • Inhibitory • Not inhibitory specific • Neutralizing • Detects total drug • Not inhibitory • Detects free drug (free, partially bound, • Detects bound drug fully bound) only Make Research Easy 6 Presentation Overview Anti-idiotype antibody introduction 1 2 Anti-idiotype antibody application 3 Anti-idiotype antibody development 4 Anti-idiotype antibody case study Make Research Easy 7 Applications of Anti-IDs 1 Pharmacokinetic (PK) Assays • Used to measure the antibody drug level in patient samples 2 Immunogenicity (anti-drug antibody) Assays • Used as a positive control or reference standard for ADA measurement Make Research Easy 8 Antibody drug market Gary Walsh, 2014, Nature Biotechnology Make Research Easy 9 Pharmacokinetic (PK) Assays Purpose: Detect and quantitate human Ab drugs in serum Human serum contains 5-9.5 mg/ml IgG1 Required sensitivity for Ab drug is in the ng/ml range Thus, assays must accurately detect Ab drug despite a million-fold excess of similar molecules Possible agents for detection include: • Antigen (i.e. drug target) • Anti-ID antibodies Make Research Easy 10 Anti-IDs for detection of Ab drugs Possible binding modes of anti-IDs: • Complex-specific anti-IDs detect bound Ab drugs directly • Antigen-blocking (neutralizing) anti-IDs detect free drug • Non-blocking (non-inhibitory) anti-IDs detect free and bound drug Antigen-blocking Non-blocking Complex-specific Anti-ID Drug Target Anti-ID Anti-ID Antibody drug Antibody drug Make Research Easy 11 Typical PK Assay Formats 1 Antigen Capture 2 Anti-ID-Bridging Anti-ID (labeled) Anti-Fc (labeled) Antibody drug (in human serum) Antibody drug (in human serum) Anti-ID Antigen 3 Anti-ID Capture Sandwich 4 Anti-ID-Antigen-Bridging Anti-Fc (labeled) Antigen (labeled) Antibody drug (in human serum) Antibody drug (in human serum) Anti-ID Anti-ID Make Research Easy 12 Immunogenicity of antibody drugs Liusong Yin, 2015, J. Immunology Research Make Research Easy 13 Immunogenicity of FDA Approved mAbs Product Form Target Indication Company Approval OKT3 (86%) Murine IgG2a K CD3 Graft reject Ortho Biotech 1986 ReoPro (6-44%) Chimeric Fab GP IIb/IIIaR Angioplasty Centocor 1994 Rituxan (1%, 3/356) Chimeric IgG1 K CD20 NHL Genentech 1997 Zenapax (14-34%) Humanized IgG1 K CD25 Graft reject Roche 1997 Remicade (10%) Chimeric IgG1 K TNF RA,CD Centocor 1998 Simulect (4/339, 2/133) Chimeric IgG1 K CD25 Graft reject Novartis 1998 Herceptin (<1%, 1/903) Humanized IgG1 K HER-2/NEU Breast cancer Genentech 1998 Synagis (1-2%) Humanized IgG1 K RSV RSV Medimmune 1998 Mylotarg (0%, 0/277) Humanized IgG4 K CD33 AML Wyeth 2000 Campath (2%, 4/211) Humanized IgG1 K CD52 CLL ILEX 2001 Zevalin (4%, 8/211) Murine IgG1 K CD20 NHL IDEC 2002 Xolair (<0.1%, 1/1723) Humanized IgG1 K IgE Asthma Genentech 2003 Bexxar (99%, 219/220) Murine IgG2a K CD20 NHL Corixa 2003 Raptiva (6.3%, 67/1063) Humanized IgG1 CD11a Psoriasis Genentech 2003 Erbitux (5%, 28/530) Chimeric IgG1 K EGF-R Colorectal cancer Imclone 2004 Avastin (0/500) Humanized IgG1 K VEGF Colorectal cancer Genentech 2004 Tysabri (10%) Humanized IgG4 K A4-integrin MS Biogen/IDEC 2004 Vectibix (0.3-4%) Human IgG2 K EGF-R Colorectal cancer Amgen 2006 Humira (5%, 58/1062) Human IgG1 K TNF RA Abbott 2002 Make Research Easy 14 Immunogenicity Assay Overview of Design Elements 1. FDA recommends a multi-tiered approach • Tier 1: A rapid, sensitive screening assay • Tier 2: Positive should then be subjected to a confirmatory assay, such as ligand or antigen competition assay • Tier 3: Further characterization: neutralization/class/isotype/titer 2. Aspects of Assay Development: • Highly sensitive • Able to detect all isotypes (IgM, IgE and IgG subtypes); carefully consider the avidity of control used to evaluate the assay; Should conduct assay performance test in the same concentration of matrix as that used to assess patient samples. • Rabbit or monkey will be the recommended host animals. • Detection of anti-idiotype antibodies is the most important assay validation for immunogenicity. • Establish negative control with a pool of sera from 5-10 non- exposed individuals Make Research Easy 15 Most common assay for immunogenicity Direct Binding ELISA Bridging ELISA Antibody drug (labeled) Anti-Hu IgG Fc (labeled) Anti-drug antibody Anti-drug antibody Antibody drug Antibody drug Anti-ID (mAb or pAb) serve as the best positive controls for Immunogenicity assay development Make Research Easy 16 Typical immunogenicity assay formats Direct and Bridging ELISA assays • Advantages: Sensitive, inexpensive, equipment readily available • Disadvantages: May not detect early immune response and may be influenced by high levels of circulating drug; false positives Radio-immuno precipitation assay (RIPA) • Advantages: sensitive, inexpensive, equipment readily available • Disadvantages: May not detect early immune response and may be influenced by high levels of circulating drug Surface Plasmon Resonance (SPR) • Advantages: Method of choice for detecting early immune response and has Ab characterization capabilities • Disadvantages: Expensive equipment, false positives Electrochemiluminescence (ECL) assay • Advantages: Sensitive, can be modified to respond in the presence of high levels of circulating drug • Disadvantages: Equipment can be expensive, may not easily detect rapidly dissociating Abs Make Research Easy 17 Presentation Overview Anti-idiotype antibody introduction 1 2 Anti-idiotype antibody application 3 Anti-idiotype antibody development 4 Anti-idiotype antibody case study Make Research Easy 18 Anti-IDs: pAb or mAb Anti-ID pAb (Immunogenicity studies) • Advantages: a heterogeneous population which mimic the real ADA incidence in human serum; less expensive • Disadvantages: heterogeneous; batch variability Anti-ID mAb (PK studies) • Advantages: homogenous; defined specificity • Disadvantages: May not represent the real ADA incidence in human serum; more expensive Make Research Easy 19 Challenges in anti-IDs development 1) CDR region of Ab may not be very immunogenic • Antigen immunogenicity: The ability of a particular molecule to elicit an immune response determined by whether the immune system can recognize the antigen 2) Percentage in antiserum very low • Most Abs raised target the Fc region • Anti-ID clone may be missed if conventional screening methods are used 3) Must optimize clone selection from numerous anti-IDs Make Research Easy 20 Overcoming the obstacles at GenScript 1) CDR region of Ab may not be very immunogenic Solution Use antibody drug-KLH conjugate as immunogen Use F(ab)2 (fragment, antigen binding) as immunogen • Remove Fc-specific antibodies Use our proprietary immunoadjuvant Adjust immunization schedule Consider different animal host Make Research Easy 21 Overcoming the obstacles at GenScript 2) Low percentage of anti-IDs in serum Solution Use proper secondary Ab (anti-mouse Fc to prevent cross- reaction with human Ig) HTP binding screening Capture ELISA to select natural epitope recognized by Ab Make Research Easy 22 Overcoming the obstacles at GenScript 3) Optimize clone selection from numerous anti-IDs Solution Epitope binning (ELISA or SPR-based) Affinity ranking (ELISA EC50, Koff and Kd ranking) Antibody pairing (for PK study) Antigen blocking (different binding modes) Make Research Easy 23 Flow chart of GenScript anti-IDs packages Services Anti-ID monoclonal antibody Anti-ID polyclonal antibody Starting material Target antibody drug 2-3mg Target antibody drug 20 mg or more Work flow QC Cross-reactivity with control IgG <10% Cross-reactivity with control IgG <10% Hybridoma cell lines, supernatants and Deliverables 0.5-3mg purified anti-ID antibody/rabbit purified anti-ID antibody (optional) Make Research Easy 24 Presentation Overview Anti-idiotype antibody introduction 1 2 Anti-idiotype antibody application 3 Anti-idiotype antibody development 4 Anti-idiotype antibody case study Make Research Easy 25 Case Study 1: Blocking and non-blocking Anti-IDs Antibody drug: Keytruda (commercial anti-PD1 pembrolizumab) Application: Currently in developing ELISA kit for Keytruda PK study 1 2 0 [PD-1, mg/ml] 0 1 0 0 0 .1 1 ) % 1 0 ( 8 0 g n i d n i 6 0 B e v i t a l 4 0 e R 2 0 0 mAb1 mAb2 mAb3 mAb4 Non-blocking Non-blocking Blocking Blocking Make Research Easy 26 Case Study 2: Anti-IDs with high specificity Antibody drug: humanized Ab Application: PK study 3 2.5 No.1 No.2 2 No.3 No.4 1.5 No.5 No.6 No.7 1 No.8 No.9 0.5 No.10 0 Antibody drug Human IgG1 Normal IgG Human serum Final sub-clones with high specificity to humanized Ab when screened against isotype control, normal human IgG and human serum.
Load more

Recommended publications
  • MINIREVIEW Idiotypic Vaccines and Infectious Diseases JACQUES R
    INFECTION AND IMMUNITY, June 1988, p. 1407-1413 Vol. 56, No. 6 0019-9567/88/061407-07$02.00/0 Copyright © 1988, American Society for Microbiology MINIREVIEW Idiotypic Vaccines and Infectious Diseases JACQUES R. HIERNAUX Laboratory of Microbial Immunity, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 INTRODUCTION If we accept the view that idiotypic interactions play a role in the regulation of the immune response to infectious The discovery of vaccination by Jenner, as well as the agents, various types of idiotypic manipulations (the injec- development of the principle of vaccines by Pasteur, had an tion of internal-image-bearing antibody being one of them) enormous impact on the eradication of many infectious could influence ongoing regulatory processes. On the basis diseases. These developments opened the road to the devel- of the idiotypic-network hypothesis, the idiotypic cascade opment of attenuated (i.e., live) or inactivated (i.e., nonin- presented in Fig. 1 can fectious) vaccines; however, such vaccines are not without be developed. Figure 1 follows problems and can have detrimental effects. Indeed, attenu- Jerne's original assumption that paratopes and idiotopes are ated vaccines can revert to a more virulent form, and distinct functional entitites. This allows us to deduce which inactivated vaccines may produce serious side effects. There interactions can potentially occur within the idiotypic cas- also are several infectious diseases for which no vaccines cade. For the sake of simplicity, I only present some of the are available. For example, many parasitic infections cannot members of the cascade and consider one or two idiotopes be prevented by vaccination.
    [Show full text]
  • Treatment of Patients with Malignant Lymphomas with Monoclonal Antibodies
    Bone Marrow Transplantation (2000) 25, Suppl. 2, S50–S53 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt Treatment of patients with malignant lymphomas with monoclonal antibodies H Tesch, A Engert, O Manzke, V Diehl and H Bohlen Klinik I fuer Innere Medizin, Universitaet zu Koeln, Koeln, Germany Summary: Results and discussion Malignant lymphomas represent a heterogenous group of B and T cell-derived malignancies. Most lymphomas Native monoclonal antibodies are sensitive to chemo- and radiotherapy, however many patients will eventually relapse. Immunothera- Since the first description of therapy using monoclonal anti- peutic approaches including monoclonal antibodies, bodies in 1979, several phase I and II trials have been cytokines or vaccination approaches may offer an alter- initiated to evaluate both safety and antitumoral activity of native treatment of chemotherapy-resistant residual this approach. Native MoAbs can kill a tumor cell through cells especially in cases with low tumor burden or various mechanisms including complement activation, anti- residual disease following chemo- or radiotherapy. body-dependent cellular cytotoxicity (ADCC), phago- Monoclonal antibodies have been successfully applied in cytosis of antibody-coated tumor cells, inhibition of cell their native form, or coupled with radioisotopes or tox- cycle progression, and induction of apoptosis.2,3 Alterna- ins to selectively destroy lymphoma cells and promising tively, MoAbs can eliminate a tumor cell by inhibiting results in early clinical trials have been obtained. Alter- growth factor receptors or molecules involved in signal natively, bispecific antibodies and idiotypic vaccination transduction and cell proliferation. strategies are used to target autologous T cells to elimin- The group of R Levy at Stanford reported on promising ate lymphoma cells.
    [Show full text]
  • In the United States Court of Federal Claims OFFICE of SPECIAL MASTERS Filed: July 28, 2020
    In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS Filed: July 28, 2020 * * * * * * * * * * * * * * * * MICHAEL PAVAN, next friend of * J.P., a minor, * PUBLISHED * Petitioner, * No. 14-60V * v. * Special Master Gowen * SECRETARY OF HEALTH * Entitlement; Significant AND HUMAN SERVICES, * Aggravation; Varicella; * Chronic Inflammatory Respondent. * Demyelinating Polyneuropathy * * * * * * * * * * * * * * * * (“CIDP”). Scott W. Rooney, Nemes Rooney P.C., Farmington Hills, MI, for petitioner. Kyle E. Pozza, United States Department of Justice, Washington, DC, for respondent. DECISION1 On January 24, 2014, Michael Pavan (“petitioner”), as next friend of J.P., a minor, filed a petition in the National Vaccine Injury Compensation Program.2 Petitioner alleges that as a result of J.P. receiving the varicella vaccination on January 28, 2011, he suffered a significant aggravation of his Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”). Amended Petition at ¶¶ 4, 5, & 16 (ECF No. 26); Petitioner’s (“Pet.”) Post-hearing Brief at 2 (ECF No. 151). Based on a full review of the evidence and testimony presented, I find that petitioner has not established by a preponderance of the evidence that the varicella vaccination significantly aggravated J.P.’s CIDP and therefore, compensation must be denied and the petition dismissed. 1 In accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012), because this opinion contains a reasoned explanation for the action in this case, this opinion will be posted on the website of the United States Court of Federal Claims. This means the opinion will be available to anyone with access to the internet. As provided by 42 U.S.C.
    [Show full text]
  • Idiotype-Recognizing T Helper Cells That Are Not Idiotype Specific*
    IDIOTYPE-RECOGNIZING T HELPER CELLS THAT ARE NOT IDIOTYPE SPECIFIC* BY MARY McNAMARA AND HEINZ KOHLER From the Department of Molecular Immunology, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, NY 14263 The network hypothesis (1) postulates that B and T cells interact via comple- mentary idiotypic structures (2). This assumption creates a satisfying symmetry in the immune system by which both compartments would use similar receptor structures encoded by a single pool of variable genes. Experimental support for the sharing of idiotypes between B and T cells has been substantial (3-6). Most of this evidence comes from the demonstration that an antiidiotype antibody functionally interacts with T cells or can bind to T cells or T cell factors. These findings, however, do not prove that T cell receptors or factors use the same genes as B cells. On the contrary, the recent failure to detect active gene rearrangements in specific T cell clones (7, 8) indicates that T cells use other than Ig genes (9). One approach to studying T cell receptors is to analyze their specificity and compare it with the specificity of B cells for the same determinant. With respect to the T-B interaction in the immune network, a comparative analysis of how B and T cells recognize idiotypes would address the question of T cell receptor specificity. In a previous study we found (10) that T helper cells which recognize idiotypes as carriers for a hapten-specific antibody response recognize the TEPC-15 (T 15) 1 proteins and MOPC-167 (M 167) equally well.
    [Show full text]
  • Theories of Antibodies Production
    THEORIES OF ANTIBODIES PRODUCTION 1. Instructive Theories a. Direct Template Theory b. Indirect Template Theory 2. Selective Theories a. Natural Selection Theory b. Side Chain Theory c. Clonal Selection Theory d. Immune Network Theory INSTRUCTIVE THEORIES Instructive theories suggest that an immunocompetent cell is capable of synthesizing antibodies of all specificity. The antigen directs the immunocompetent cell to produce complementary antibodies. According to these theories the antigen play a central role in determining the specificity of antibody molecule. Two instructive theories are postulated as follows: Direct template theory: This theory was first postulated by Breinl and Haurowitz (1930). They suggested that a particular antigen or antigenic determinants would serve as a template against which antibodies would fold. The antibody molecule would thereby assume a configuration complementary to antigen template. This theory was further advanced as Direct Template Theory by Linus Pauling in 1940s. Indirect template theory: This theory was first postulated by Burnet and Fenner (1949). They suggested that the entry of antigenic determinants into the antibody producing cells induced a heritable change in these cells. A genocopy of the antigenic determinant was incorporated in genome of these cells and transmitted to the progeny cells. However, this theory that tried to explain specificity and secondary responses is no longer accepted. SELECTIVE THEORIES Selective theories suggest that it is not antigen, but the antibody molecule that play a central role in determining its specificity. The immune system already possess pre-formed antibodies of different specificities prior to encounter with an antigen. Three selective theories were postulated as follows: Side chain theory: This theory was proposed by Ehrlich (1898).
    [Show full text]
  • Jerne's Anti-Idiotypic Network Theory Cannot Explain Self-Nonself
    Journal of Alternative Medicine Research ISSN: 1939-5868 Volume 1, Issue 4, pp.439-444 © 2009 Nova Science Publishers, Inc. Human development XVII: Jerne’s anti-idiotypic network theory cannot explain self-nonself discrimination Søren Ventegodt∗1,2,3,4,5, Tyge Dahl Abstract Hermansen1, Isack Kandel6,7 and Joav Merrick5,7,8,,9 In this paper we propose that self-nonself discrimination 1 takes place at a supra-cellular systemic level and involves Quality of Life Research Center, Classensgade 11C, 1 selective activation of immune cell precursors. We discuss sal, DK-2100 Copenhagen O, Denmark; this activation, the further differentiation to active 2Research Clinic for Holistic Medicine and lymphocytes, and the following immune response induced 3Nordic School of Holistic Medicine, Copenhagen, by the system permitting all relevant information to be Denmark; involved in the “decision” process in a dynamic way. We 4Scandinavian Foundation for Holistic Medicine, discuss Jerne’s immunological network theory based on the capability of self-nonself discrimination and we discuss if Sandvika, Norway; 5 his immunological network theory is able to carry out such Interuniversity College, Graz, Austria; self-nonself discrimination. We argue that this is not the 6 Faculty of Social Sciences, Department of Behavioral case. We discuss the immune tolerance that seems not to be Sciences, Ariel University Center of Samaria, Ariel, transferred with the immune cells, what Jerne’s network Israel; model involves as a necessity. We discuss Jerne’s 7National Institute of Child Health and Human idiotypical network’s capability of being expanded to include T-cells. Also here we argue that this is not the case.
    [Show full text]
  • Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: an Update Alejandro López-Requenaa,B and Oscar R
    The Open Immunology Journal, 2009, 2, 1-8 1 Open Access Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update Alejandro López-Requenaa,b and Oscar R. Burrone*,b aDepartment of Antibody Engineering, Center of Molecular Immunology, P.O. Box 16040, Havana 11600, Cuba bMolecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy Abstract: The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation. One ma- jor challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells. We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas. Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed. Keywords: Anti-idiotypic antibodies, NeuGc, ganglioside, idiotype, B cell lymphoma. INTRODUCTION antigen. The generation of anti-idiotypic antibodies against Ab2 (anti-Ab2 or Ab3) with the same specificity of the Ab1 From the pioneer works by Oudin and Kunkel [1, 2], (Ab1’) can be impaired by the peripheral tolerance mecha- where the existence of individual antigenic determinants of nisms of the organism even when the Ab2 carries the “inter- the immunoglobulins (idiotopes) was demonstrated, to nal image” of the antigen [6]. Jerne’s Idiotypic Network Theory [3]; through Bona’s “regu- latory idiotope” [4] and Coutinho’s “second generation” Anti-idiotypic antibodies have been widely used for can- networks [5], the theory around anti-idiotypic antibodies has cer immunotherapy [7].
    [Show full text]
  • Anti-Idiotypic Antibodies Against a Human Multiple Organ- Reactive Autoantibody
    Anti-idiotypic antibodies against a human multiple organ- reactive autoantibody. Detection of idiotopes in normal individuals and patients with autoimmune diseases. K Essani, … , P R McClintock, A L Notkins J Clin Invest. 1985;76(4):1649-1656. https://doi.org/10.1172/JCI112150. Research Article We have recently isolated and characterized a human monoclonal autoantibody, MOR-h1 (multiple organ-reactive human 1), that reacts with antigens in multiple organs and have shown that this antibody binds to human growth hormone and a 35,000-mol wt protein. In the present study we generated three monoclonal anti-idiotypic antibodies (4E6, 3E5, and 3F6) against MOR-h1. These anti-idiotypic antibodies specifically reacted with MOR-h1 and not with 26 other multiple organ- reactive monoclonal IgM autoantibodies nor with pooled human IgM (myeloma proteins). The binding of the anti-idiotypic antibodies to MOR-h1 was inhibited by both human growth hormone and the 35,000-mol wt protein, which strongly suggests that these antibodies react with epitopes at or near the paratope on MOR-h1. The results of competitive binding experiments revealed that the epitope recognized by 4E6 is distinct from that recognized by 3E5 and 3F6. Using these anti-idiotypic antibodies, lymphocytes and sera from normal individuals were tested for the presence of the 4E6 and 3E5/3F6 idiotopes. By indirect immunofluorescence, the 4E6 idiotope was detected on an average of 1.1% of normal circulating B lymphocytes, and by enzyme-linked immunosorbent assays, the 4E6 and to a lesser extent the 3E5/3F6 idiotopes were found on IgG molecules in sera of normal individuals.
    [Show full text]
  • Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
    antibodies Review Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy Aliya K. Stanova 1, Varvara A. Ryabkova 1 , Sergei V. Tillib 2,3, Vladimir J. Utekhin 1, Leonid P. Churilov 1,4,* and Yehuda Shoenfeld 1,5 1 Department of Pathology and Laboratory of the Mosaic of Autoimmunity, Saint Petersburg State University, 199034 Saint Petersburg, Russia; [email protected] (A.K.S.); [email protected] (V.A.R.); [email protected] (V.J.U.); [email protected] (Y.S.) 2 Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia; [email protected] 3 Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia 4 Saint Petersburg Research Institute of Phthisiopulmonology, 191036 Saint Petersburg, Russia 5 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Tel Aviv University School of Medicine, Tel-Hashomer, Ramat Gan 52621, Israel * Correspondence: [email protected] Received: 30 April 2020; Accepted: 26 May 2020; Published: 28 May 2020 Abstract: Anti-idiotypic antibodies (anti-IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti-IDs: α, β, γ, ", and δ. Due to the ability of internal-image anti-IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti-IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti-IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications.
    [Show full text]
  • Targeting Lymphoma with Precision Using Semisynthetic Anti-Idiotype Peptibodies
    Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies James Torchiaa, Kipp Weiskopfa, and Ronald Levya,1 aDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 Contributed by Ronald Levy, March 16, 2016 (sent for review December 14, 2015; reviewed by Sherie Morrison and Thomas Waldman) B-cell lymphomas express a functionally active and truly tumor- peptides can cluster BCR and trigger signaling that results in specific cell-surface product, the variable region of the B-cell apoptosis of lymphoma cells in vitro (17). Because they can be receptor (BCR), otherwise known as idiotype. The tumor idiotype produced rapidly and inexpensively by solid-phase synthesis, idi- differs, however, from patient to patient, making it a technical otype-binding peptides might represent a practical anti-idiotype challenge to exploit for therapy. We have developed a method of therapy; however, they are cleared quickly from serum, as is typ- targeting idiotype by using a semisynthetic personalized thera- ical for small peptides, and are therefore not sufficient to induce peutic that is more practical to produce on a patient-by-patient tumor clearance in vivo. To overcome this limitation, we designed basis than monoclonal antibodies. In this method, a small peptide a system to effect a chemical fusion between idiotype-binding with affinity for a tumor idiotype is identified by screening a library, peptides and a recombinant Ig Fc domain, yielding a semisynthetic chemically synthesized, and then affixed to the amino terminus of a peptibody (Fig. 1B). This modular design allows for the synthetic premade IgG Fc protein. We demonstrate that the resultant semi- production of the patient-specific oligopeptide and bulk biologic synthetic anti-idiotype peptibodies kill tumor cells in vitro with production of the patient-invariant biologic Fc domain.
    [Show full text]
  • Anti-Idiotype Antibodies: Powerful Tools for Antibody Drug Development
    Anti-Idiotype Antibodies: Powerful Tools for Antibody Drug Development Michelle Parker, Ph.D. [email protected] Table of Contents 1 What is an Anti-Idiotype Antibody? 2 Anti-Idiotype Antibody Applications 3 Obstacles & Solutions to the Generation of Anti-Idiotype Abs 4 Downstream Assay Development 5 Features of GenScript’s Anti-Idiotype Antibody Services 6 GenScript Anti-Idiotype Antibody Packages Make Research Easy 2 Antibody: Structure and Function Antibody (Ab): Recognition proteins found in the serum and other bodily fluids of vertebrates that react specifically with the antigens that induced their formation. Overall structure: • 2 identical light chains (blue) • 2 identical heavy chains (green/purple) Variable regions and constant regions 5 classes of Abs: • IgG, IgA, IgM, IgD, IgE • All contain either λ or κ light chains • Biological effector functions are mediated by the C domain Chemical structure explains 3 functions of Abs: 1. Binding versatility 2. Binding specificity 3. Biological activity Make Research Easy 3 Antibody Binding Regions Idiotope – the antigenic determinants in or close to the variable portion of an antibody (Ab) Paratope – the part of an Ab that recognizes an antigen, the antigen-binding site of an Ab or complementarity determining region (CDR) Epitope – the part of the antigen to which the paratope binds Make Research Easy 4 Anti-Idiotype Antibodies Anti-idiotype antibodies (Anti-IDs) – Abs directed against the paratope (or CDR region) of another Ab Hypervariable regions (or the idiotype
    [Show full text]
  • Unresolved Issues in Theories of Autoimmune Disease Using Myocarditis As a Framework
    Journal of Theoretical Biology 375 (2015) 101–123 Contents lists available at ScienceDirect Journal of Theoretical Biology journal homepage: www.elsevier.com/locate/yjtbi Unresolved issues in theories of autoimmune disease using myocarditis as a framework Robert Root-Bernstein a,1, DeLisa Fairweather b,n a Michigan State University, Department of Physiology, 2174 Biomedical and Physical Sciences Building, East Lansing, MI 48824, USA b Johns Hopkins Bloomberg School of Public Health, Department of Environmental Health Sciences, 615 N. Wolfe Street, Room E7628, Baltimore, MD 21205, USA HIGHLIGHTS Clinical and experimental evidence support some aspects of all theories. Critical comparative studies differentiating between theories and models needed. Theories monocausal but animal models suggest multi-factorial cause of disease. Theories do not adequately explain adjuvant, innate immunity or sex differences. New synthetic theory needed integrating anomalies, innate and adaptive immunity. article info abstract Article history: Many theories of autoimmune disease have been proposed since the discovery that the immune system Received 10 July 2014 can attack the body. These theories include the hidden or cryptic antigen theory, modified antigen Received in revised form theory, T cell bypass, T cell–B cell mismatch, epitope spread or drift, the bystander effect, molecular 10 November 2014 mimicry, anti-idiotype theory, antigenic complementarity, and dual-affinity T cell receptors. We critically Accepted 20 November 2014 review these theories and relevant mathematical models as they apply to autoimmune myocarditis. All Available online 4 December 2014 theories share the common assumption that autoimmune diseases are triggered by environmental Keywords: factors such as infections or chemical exposure. Most, but not all, theories and mathematical models are Autoimmune disease theories and modeling unifactorial assuming single-agent causation of disease.
    [Show full text]